...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Separation of graft-versus-host disease from graft-versus-leukemia responses by targeting CC-chemokine receptor 7 on donor T cells.
【24h】

Separation of graft-versus-host disease from graft-versus-leukemia responses by targeting CC-chemokine receptor 7 on donor T cells.

机译:通过将CC-趋化因子受体7靶向供体T细胞,将移植物抗宿主病与移植物抗白血病反应分离。

获取原文
获取原文并翻译 | 示例

摘要

CC-chemokine receptor 7 (CCR7) is expressed on the surface of naive T cells, and plays a critical role in their movement into secondary lymphoid tissue. Here, we show that murine T cells lacking CCR7 (CCR7(-/-)) generate attenuated graft-versus-host disease (GVHD) responses compared with wild-type (WT) cells, with the difference varying inversely with the degree of major histocompatibility complex (MHC) disparity between the donor and recipient. CCR7(-/-) T cells exhibited an impaired ability to traffic to recipient lymph nodes, with an increased capacity to home to the spleen. CCR7(-/-) T cells, however, demonstrated a reduced ability to undergo in vivo expansion in the spleen due to impaired interactions with splenic antigen-presenting cells. On a cellular level, CCR7(-/-) T cells were functionally competent, demonstrating a normal in vitro proliferative capacity and a preserved ability to produce inflammatory cytokines. Importantly, CCR7(-/-) T cells were capable of generating robust graft-versus-leukemia (GVL) responses in vivo, as well as complete donor T-cell reconstitution. CCR7(-/-) regulatory T cells were able to protect against lethal GVHD when administered before WT conventional T cells. Our data suggest that CCR7 inhibition in the early posttransplantation period may represent a feasible new therapeutic approach for acute GVHD attenuation without compromising GVL responses.
机译:CC趋化因子受体7(CCR7)在幼稚T细胞的表面表达,并在其进入​​次级淋巴组织中起关键作用。在这里,我们表明,与野生型(WT)细胞相比,缺少CCR7(CCR7(-/-))的鼠T细胞产生的移植物抗宿主病(GVHD)减毒反应,差异随主要程度的变化呈反比关系。供体和受体之间的组织相容性复合体(MHC)差异。 CCR7(-/-)T细胞显示出运至受体淋巴结的能力受损,并具有脾脏归巢的能力。然而,由于与脾抗原呈递细胞的相互作用受损,CCR7(-/-)T细胞表现出降低的在脾脏中进行体内扩增的能力。在细胞水平上,CCR7(-/-)T细胞具有功能性,证明了正常的体外增殖能力和产生炎性细胞因子的保留能力。重要的是,CCR7(-/-)T细胞能够在体内产生强大的移植物抗白血病(GVL)反应,以及完整的供体T细胞重构。当在WT传统T细胞之前给药时,CCR7(-/-)调节性T细胞能够预防致命的GVHD。我们的数据表明,在移植后早期抑制CCR7可能代表一种可行的新治疗方法,可用于急性GVHD衰减而不损害GVL反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号